 |
 |
|
Calling all drug delivery dealmakers!Dear Customers, Welcome to the latest edition of DDR E-News, your monthly news, trends and deal making resource for companies active in the drug delivery sector. The current issue of DDR E-News highlights the increase in licensing deals towards the end of 2006 and the unusually high deal making activity of global companies. Technology features from NanoDel Technologies, Advanced Technology Pharma, Bespak, Direct-Haler and others are also included. As always, we hope that the current issue of DDR E-News will be a valuable resource to support your deal making activities. Best wishes, |
||
 |
 |
Market News and TrendsDuring December 2006, PharmaDeals® Agreements recorded a total of 15 deals relating to drug delivery, nine lower than the number recorded for the previous month. Despite the fewer number of deals, a similar pattern to that seen in November was also seen in December. Global and established companies continued to be involved in a higher number of deals than they had been earlier in the year. Only three deals during December took place between start-up and emerging companies. By contrast, global companies were involved in six deals and established companies in five transactions. A result of this unusually high level of deal making activity by larger companies was that a number of deals had significantly high potential financial values. The majority of December’s deals involved licensing agreements. Read more... |
||
|
|
||
Featured ArticleTransport of Doxorubicin Across the Blood Brain Barrier using Biologically-Compatible Polymeric Nanoparticles: A ReviewBrain tumours belong to the most aggressive cancers in humans, with 180,000 new cases in the US alone. Normally, anti-cancer drugs do not cross the blood-brain barrier. The inaccessibility of the tumour tissue results in an insufficient response to cancer drugs. In this article, Kerstin Ringe of NanoDel Technologies, discusses NanoDel’s objective of achieving a sufficient supply of Doxorubicin in the brain via a nanoparticle-mediated drug transport. Read more... |
 |
||
|
|
||
 |
Company ProfilesAdvanced Technology Pharma, Bespak, Direct-Haler, Fertin Pharma |
||
|
|
||
Drug Delivery OpportunitiesDo you know about our drug delivery opportunities database? If you're interested in gaining visibility for your opportunity without giving away too much information, you should register with us now! Information about your opportunity will be posted on the website without detailing your firm's name, thereby protecting your business opportunity. Only those firms which are truly interested in your opportunity will gain access to your valuable product information.For the latest information about our Drug Delivery Opportunities, visit our website or alternatively, request a password to submit your opportunity online. Featured Opportunity Compositions and Methods for Targeting a Polypeptide to the CNS Administrative Route - Undisclosed Indication - Modular targeting molecules that can selectively penetrate the blood-brain barrier Licence code - LO-0406-42 |
 |
||
|
|
||
 |
Ensure you receive your copy of the Drug Delivery Report Autumn / Winter 2006For deal makers actively assessing drug delivery technologies, the current complimentary issue of the Drug Delivery Report is a must. The DDR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas.Apply to receive the next edition of the DDR Find out more about promoting your company |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence - we work with clients to drive greater value from their deals.
If you do not wish to receive DDR E-News in future, please e-mail enquiries@pharmaventures.com with the words UNSUBSCRIBE DDR as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail enquiries@pharmaventures.com with REMOVE as the subject.
For more details contact
Kate Atherton, Publishing Editor, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@pharmaventures.com